Vera Therapeutics (VERA) Earnings Date & Reports

Key Takeaways

• Vera Therapeutics reported its first-ever net product revenue of $10.3 million in the third quarter of 2026, driven by the launch of TRUTAKNA following FDA accelerated approval in July 2026.
• The company posted a net loss of $93.7 million, or $1.30 per share, beating the consensus estimate of roughly -$1.61 to -$1.62 per share.
• Approximately 700 Patient Start Forms (PSFs) have been received since launch, signaling early commercial uptake in IgA nephropathy (IgAN).
• Research and development (R&D) spending fell to $41.3 million from $56.5 million a year ago, while selling, general and administrative (SG&A) expenses rose sharply to fund the commercial rollout.
• Vera ended the quarter with $384.0 million in cash, cash equivalents, and marketable securities, and submitted a supplemental Biologics License Application (sBLA) seeking full approval of TRUTAKNA.
• For more details on Vera Therapeutics' Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages.
• To discover AI-driven trading ideas across the market, explore the Trending AI Robots.

Earnings Context and Why It Matters

Vera Therapeutics' third-quarter 2026 report marks a pivotal transition: the company moved from a clinical-stage biotech to a commercial-stage enterprise. After receiving accelerated approval from the U.S. Food and Drug Administration (FDA) for TRUTAKNA (atacicept-vymj) on July 7, 2026, Vera began generating product revenue for the first time in its history. This quarter is therefore a key test of the drug's real-world launch execution, payer dynamics, and physician adoption in IgA nephropathy, a progressive kidney disease affecting roughly 160,000 diagnosed patients in the U.S. Investors are watching whether early patient demand converts into sustained revenue growth and whether operating costs remain disciplined as the company scales its commercial infrastructure.

Reported Results

For the third quarter ended September 30, 2026, Vera Therapeutics reported net product revenue of $10.3 million, compared with no product revenue in the prior-year period. This topped consensus estimates, which ranged from approximately $3.4 million to $3.78 million.

The company posted a net loss of $93.7 million, or $1.30 per share, versus a net loss of $80.3 million, or $1.26 per share, a year earlier. Despite the wider absolute loss, the per-share figure beat the analyst consensus of roughly -$1.61 to -$1.62, partly reflecting a larger share count following recent equity financings.

Research and development (R&D) expenses declined to $41.3 million from $56.5 million, as certain manufacturing costs were reclassified as inventory after the approval. Selling, general and administrative (SG&A) expenses rose to $61.4 million from $27.5 million, reflecting investment in the commercial launch. Vera ended the quarter with $384.0 million in cash, cash equivalents, and marketable securities, down from $714.6 million at the end of 2025.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. If you are looking to streamline your research process, consider exploring the AI Screener to uncover new investment ideas.

Market Reaction and Investor Sentiment

Vera Therapeutics shares fell roughly 5.7% in the session following the report, closing near $30.14. The decline suggests that, despite a revenue beat and better-than-expected per-share loss, investors focused on the widening net loss and elevated launch spending. Early reception to TRUTAKNA appears encouraging, with approximately 700 Patient Start Forms received, but the market remains attentive to how quickly those forms convert into filled prescriptions and sustained revenue. The upcoming full-approval review and the planned European filing are likely to shape sentiment in the quarters ahead.

Forward Outlook and Key Factors to Monitor

Looking ahead, the central question for Vera Therapeutics is whether TRUTAKNA's early launch momentum can translate into durable, growing revenue. Investors should track the trajectory of Patient Start Forms, the pace of payer coverage decisions, and how quickly new patient starts convert into reimbursed prescriptions.

On the regulatory front, Vera submitted a supplemental Biologics License Application (sBLA) to the FDA on November 3, 2026, seeking full approval of TRUTAKNA based on the ORIGIN 3 final efficacy analysis. That analysis demonstrated stabilization of kidney function through 104 weeks, with an annualized eGFR slope of -0.6 mL/min/1.73m²/year for TRUTAKNA versus -5.6 mL/min/1.73m²/year for placebo.

Additionally, the company plans to submit a Marketing Authorisation Application to the European Medicines Agency in the first quarter of 2027, which could expand the addressable market beyond the current U.S. accelerated-approval label.

Cost discipline will remain another key factor. While R&D spending declined in the quarter, SG&A expenses rose materially as Vera built out its commercial organization. With roughly $384 million in cash and an additional $75 million drawn under its debt facility in late October, the company has meaningful runway, but the balance between launch investment and operating losses will be closely watched. As always, these observations are grounded in reported data and do not constitute investment advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations